Open AccessConcomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor
Author(s) -
Yiqiang Xie,
Ning Su,
Wei Zhou,
Li An,
Xiang Li,
Weiwei Li,
Huichun Zhan,
Wenchang Cen,
Jinxing Hu
Publication year - 2021
Publication title -
cancer management and research
Language(s) - Uncategorized
Resource type - Journals
ISSN - 1179-1322
DOI - 10.2147/cmar.s326349
Subject(s) - medicine , concomitant , epidermal growth factor receptor , adenocarcinoma , oncology , lung cancer , tyrosine kinase inhibitor , survival rate , gastroenterology , cancer
Limited studies have clearly demonstrated the effect of EGFR-TKI in the treatment of EGFR mutant NSCLC patients with underlying pulmonary disease, like pulmonary tuberculosis (PTB). Here, we conducted the study to evaluate the impact of PTB on survival of Chinese EGFR mutant lung adenocarcinoma (LUAD) patients that underwent EGFR-TKI treatment.